GET DAILY SIGNALSCo-Diagnostics (CODX) Reports +95% Revenue Growth in Q3 2026 as Losses Narrow
Key Takeaways
- Co-Diagnostics (CODX) reported third-quarter 2026 revenue of approximately $283,000, up nearly 95% from the prior-year period.
- GAAP net loss came in at $1.01 per share, beating the consensus estimate of a $1.25 loss.
- Operating loss narrowed to roughly $6.3 million as the company continued its cost-discipline push.
- Adjusted EBITDA improved from the prior-year period.
- Cash and cash equivalents fell to about $0.7 million at quarter-end, down from roughly $11.9 million at the end of 2025.
Putting the Results in Context
Co-Diagnostics (CODX) is still in a pre-commercialization stage, with its efforts centered on advancing the Co-Dx PCR testing platform instead of driving significant product sales. That reality shifts the focus of each earnings release toward cash management, clinical advancements, and regulatory progress. The third quarter of 2026 delivered positive signals on both revenue and spending: product sales nearly doubled year over year while operating costs kept trending lower. For investors, the numbers help assess whether the company can keep its development programs on track and position itself for future commercial launches without running down its balance sheet too quickly. The report also highlights how management is emphasizing efficiency ahead of a potential turning point.
What the Quarter Actually Showed
For the period ended September 30, 2026, Co-Diagnostics (CODX) posted revenue of approximately $283,000, a nearly 95% rise from roughly $145,000 in the same quarter a year earlier. The GAAP net loss of $1.01 per share came in better than the consensus forecast of a $1.25 loss, and total revenue exceeded analyst expectations. Operating expenses dropped about 12% year over year, helped by lower personnel and stock-based compensation costs along with reduced development outlays on the Co-Dx PCR platform. The net loss for the quarter was approximately $6.3 million, a bit wider than the prior-year amount because of a non-recurring tax benefit that had supported the year-ago results. Adjusted EBITDA improved to a loss of roughly $5.9 million. Cash and cash equivalents stood at about $0.7 million at quarter end. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
How the Market Is Responding
Shares of Co-Diagnostics (CODX) have tended to react more to news around its diagnostic platform and funding plans than to revenue headlines by themselves. This quarter’s beats on both earnings per share and revenue would normally point to a supportive near-term response, although the thin cash position and ongoing net losses stay top of mind for many investors. Sentiment remains tied to updates on clinical evaluations, regulatory filings, and international joint ventures, which continue to be viewed as the main long-term value drivers. The narrower operating loss and tighter expense control came across as evidence that management is stretching its financial runway while moving closer to commercialization.
What to Watch Going Forward
The key variable ahead is the company’s capacity to finance its pipeline and reach commercial launch. With cash and cash equivalents near $0.7 million at the end of September 2026, down sharply from year-end levels, balance-sheet management will stay in focus. Investors will look for signs of additional financing, grant support, or strategic deals that could bolster liquidity.
On the operational side, attention stays on the Co-Dx PCR platform and how its tests advance through clinical evaluations and regulatory submissions. International efforts, including the joint ventures in India and the Middle East, also merit watching as possible routes to future revenue and local manufacturing.
Cost trends remain relevant too. The company has shown solid expense discipline, and maintaining that while pushing clinical work forward will be important. Any news on manufacturing automation, product deployment steps, or fresh commercial partnerships could act as catalysts. As always, these developments need to be weighed against ongoing losses and the still-early revenue base.
AI Tools I Rely On for Research
When analyzing names like Co-Diagnostics (CODX), I often turn to Tickeron’s AI Screener to quickly filter for technical patterns, fundamentals, and momentum signals across thousands of stocks. It helps surface comparable ideas and track shifts in sentiment without spending hours on manual work, which keeps my review process more efficient and focused.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
CODX in downward trend: price dove below 50-day moving average on October 13, 2026
CODX moved below its 50-day moving average on October 13, 2026 date and that indicates a change from an upward trend to a downward trend. In 37 of 41 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 13, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CODX as a result. In 74 of 86 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 86%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CODX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for CODX entered a downward trend on November 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator shows that the ticker has stayed in the oversold zone for 20 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 20 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The Moving Average Convergence Divergence (MACD) for CODX just turned positive on November 11, 2026. Looking at past instances where CODX's MACD turned positive, the stock continued to rise in 33 of 40 cases over the following month. The odds of a continued upward trend are 82%.
CODX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 6 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 45 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.141) is normal, around the industry mean (4.142). P/E Ratio (-0.010) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.010) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (3.171) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 98 (best 1 - 100 worst), indicating slightly worse than average price growth. CODX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CODX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of molecular diagnostics products and tests that represents a radical new advancement in the understanding of the molecular interactions of DNA
Industry MedicalNursingServices
Advertisement